Scientists engineered bacteria as Trojan horses to transport cancer-killing viruses directly into tumor cores, bypassing immune clearance. This targeted delivery system enables the virus to replicate locally within tumors and destroy malignant cells while safety mechanisms prevent viral spread outside the tumor environment. This novel approach offers a promising platform for precise, effective cancer immunotherapies with reduced systemic toxicity, representing a convergence of microbiology and virotherapy with potential clinical impact.